We describe the case of a 30-year-old female with no family history of psoriasis and suffering from Crohn's disease successfully treated with infliximab at the dosage of 5 mg/kg. At the 15 th week from the start of therapy, the patient developed a palmoplantar pustular psoriasis, which spread to the arms, trunk and scalp with erythematosquamous plaques. Deeming the dermatitis onset due to the anti-TNF-a, we decided to discontinue infliximab, while starting with a topical therapy with emollients and corticosteroids and a systemic therapy with cyclosporine. These treatments achieved a clear improvement of psoriasis after 2 months and a complete regression of skin lesions after 4 months. Several cases have been reported of psoriasis induced by anti-TNF-a, which have shown to exert an effective therapeutic action on this disease. The pathogenic mechanism of such a paradoxical effect has not yet been explained, though a number of hypotheses were proposed, among which one of the most intriguing is that the rapid and strong blockade of TNF-a could result in an enhancement of INF-a activity with consequent induction of psoriasis.
Anti-TNF-n agents, among which the chimeric monoclonal antibody infliximab, proved very effective in treating chronic inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease (CD), Behcet's disease and, recently, psoriasis. Paradoxically, the induction of psoriasiform lesions by these agents has been reported in recent years (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . We report the case of a female patient suffering from CD who developed psoriatic lesions following treatment with infliximab.
MATERIALS AND METHODS

Patient
A 30-year-old woman with no personal or family history of psoriasis, suffering for 3 years from CD, resistant to mesalazine and prednisone, was put on therapy with infliximab in June 2007, with an induction dose of 5 mg/kg i.v. at weeks 0, 2 and 6 and a subsequent maintenance scheme of 5 mg/kg i.v. every 8 weeks.
Though the therapy with anti-TNF-a resulted in a complete resolution of gastrointestinal symptoms during the induction phase, a rash with small pustules on an erythematous basis appeared on the plantae 15 weeks after starting the therapy. Subsequently, the rash extended to the palms and then a rash with erythematosquamous plaques developed progressively involving the trunk, arms and scalp; in this last localization the scales were thick and adherent. The plantar lesions were sharply painful on deambulation. A clinical diagnosis of psoriasis was made (PASI = 44.8) and no histological examination was deemed necessary due to the clinical evidence. The medical history did not reveal any previous intake of drugs inducing psoriasis and was negative for allergic diseases or reactions. In addition, the examinations did not reveal any infectious focus, either dental, gynecologic or otorhynolaryngologic. Microbiological cultures from pustule content were negative for bacterial growth and no antibodies against nuclei or double-helix DNA were detected. At the onset of rash, only a topical antipsoriatic treatment was given, consisting in class II corticosteroids, keratolytics (2% salicylic acid) and emollients. This treatment proved ineffective, being accompanied by worsening and spreading of skin lesions. Therefore, we decided to discontinue the infliximab therapy (the patient did not receive the 5 th infusion) and to administer a systemic treatment with cyclosporine (CyA) at the dosage of 4 mglkg/day for 5 months along with a local emollient therapy.
RESULTS
After two months oftherapy, there was a complete remission of skin lesions (PASI = 12.9) with a reduction of erythema, desquamation, pustulosis and pain on deambulation; some scalp lesions left alopecia areas. Four months later, a complete remission of psoriatic lesions was achieved, with disappearance of pain on deambulation and persistence of partially resolving alopecia patches on the scalp. Six month after discontinuation of anti-TNF-n and 1 month after completing the treatment with CyA, psoriasis, as well as CD, was still in complete remission, and the alopecia patches on the scalp exhibited an almost complete regrowth of hair.
DISCUSSION
Though the prevalence of psoriasis is higher in patients with CD (8.9% to 11.2%) than in the general population (2% to 3%) (7, (16) (17) , we believe that, in our patient, psoriasis was induced by the treatment with infliximab, based on the negativity of both personal and family history for psoriasis or precipitating factors like drugs, infections, stress and on the clear temporal relationship with the administration of anti-TNF-n. In addition, the literature discloses a higher prevalence of psoriasis in patients with CD and treated with anti-TNF-a (17%) than in similar patients untreated with TNF-a inhibitors (7) .
A recent review by Wollina (1) points out that the induction of psoriasis in course of therapy with anti-TNF-a also occurs with etanercept and adalimumab, highlighting that this is a "class effect", not restricted to a single molecule. In addition, in most cases, psoriasis induced by anti-TNF-a belongs to the pustular palmoplantar and/or plaque psoriasis variants, occurring in patients with no family history of psoriasis and after a varying lapse of time from the start of therapy (1) . Though psoriasis induced by anti-TNF-a agents does not usually prompt for discontinuation of treatment, being moderately severe and manageable just with a topical treatment, in some cases it may be so severe and unresponsive to local therapies as to require the discontinuation of TNF-a inhibitor and the administration of another immunosuppressant agent, like CyA in our case. Moreover, the discontinuation of TNF-a inhibitor and the prompt administration of another immunosuppressant agent become necessary in cases of severe involvement of the scalp, in order to prevent definitive alopecia (5) . Genetic studies revealed that two genes related to psoriasis, IL 12B and IL 23R, also confer susceptibility to other inflammatory conditions, such as CD (18) . ILl2, a cytokine secreted mainly . by activated myeloid dendritic cells (mDCs), plays a major role in the expansion and differentiation of Thl cells. A predisposition to self-immunity could be explained by abnormal levels ofILl2 (19) . IL23, which is secreted by human dendritic cells (DCs) exposed to Gram-negative bacteria, is a cytokine leading to self-immune diseases, including psoriasis and intestinal inflammatory disease; this cytokine promotes the development and expansion of an activated third-Cfr-l" T cell subset, known as Th17 which produces ILl 7, ULl7F and TNF (19) . IL-17 mediates powerful effects on stromal cell in many tissues, resulting in the production of inflammatory cytokines and recruitment of leucocytes (20) . High levels of ILl 7 and IL23p 19 are present in CD and psoriasis and such cytokines could be considered mediators of these diseases (19) . In addition, the gene CDKAL 1 on the chromosome 6p22 showed a close relation between CD and psoriasis (18) . Other studies revealed an increased frequency of the Ig heavy-chain HS 1,2-A enhancer *2 allele in psoriasis and intestinal inflammatory disease (21) (22) . The hypothesis that can be formulated about the exact mechanism by which psoriatic lesions develop in the course of treatment with anti-TNFa drugs derives from the existence of a cross-regulation between TNF and IFN-a (23) . Plasmacytoid dendritic cells (pDCs) produce great amounts of IFN-a/( type I IFN) in response to viral infections (19, 23) , besides great amounts of TNF and other cytokines. This leads to the generation of activated (mature) DCs derived from pDCs via autocrine TNF and from immature mDCs via paracrine type I IFN (19) . Once mature, pDCs become incapable of producing type I IFN (19, 23) ; it is therefore clear that TNF inhibits pDCs from producing IFN by inducing their maturation (19, 23) , with the consequence that the neutralization of endogenous TNF causes pDCs to remain in an immature status with consequent increase in IFN-a secretion and release (19, 23) . By inducing mDC activation/maturation, IFN-a brings about the differentiation and expansion of Thl cells (19, 24) . The release of cytokines, in particular IFNy, IL-2 and TNF-a, leads to histological changes and to psoriatic phenotype (25) . In addition, TNF has also been shown to regulate IFN-a production by inhibiting pDC generation from hematopoietic progenitor cells (HPCs) (23) . Therefore, we can hypothesize that TNF acts as an antagonist of the type I IFN pathway. However, more cases of psoriasis induced by TNF-a inhibitors should be collected and analyzed in order to identify the risk factors for the development of such a paradoxical effect and to understand its physiopathologic mechanism. Furthermore, this adverse event may encourage further research for a better understanding of its pathogenesis and a consequent better treatment of psoriasis.
